Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Remaining Performance Obligations (RPO) by Year
Remaining Performance Obligations (RPO) — Total [legacy through Q3 2023] ($M) ($M)
Pfizer Remaining Performance Obligations (RPO): $15,000M in FY2022, down 56.4% from a year earlier. No newer figure appears in the documents we track.
Where the FY2022 figure comes from
Source: Form 10-K (filed 2023-02-23) ↗
Reported in Form 10-Q / 10-K Revenue Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Remaining Performance Obligations (RPO) — Total [legacy through Q3 2023] ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2022 | Dec 31, 2022 | 15,000 | -56.4% | Form 10-K (filed 2023-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 34,400 | – | Form 10-K (filed 2022-02-24) ↗ |
Cite this data
StockData. (2026). Pfizer Remaining Performance Obligations (RPO) ($M), annual FY2021–FY2022 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/rpo-total-leg
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.